Bharat Biotech’s intranasal vaccine for COVID-19
Recently, Bharat Biotech has completed the Phase II trial of the intranasal (injected through the nose) Covid vaccine, BBV 154.
It is a novel adeno virus carrier vaccine.
Profit:
Other vaccines only produce antibodies, but intranasal vaccines produce antibodies as well as reduce the risk of infection.
Easy dispensing – no syringe and needle required.
Additional immune response:
- In addition to immunity in the blood, it also activates the immunity of cells found in the tissues of the nose and mouth and lungs.
- Only a small amount of this will usually be needed, usually 0.1 ml.
Source – PIB
